董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nancy Snyderman | 女 | Director | 71 | 22.57万美元 | 未持股 | 2023-05-01 |
| Esteban López | 男 | Director | 50 | 21.82万美元 | 未持股 | 2023-05-01 |
| Jane E. Kiernan | 女 | Director | 62 | 22.82万美元 | 未持股 | 2023-05-01 |
| David M. Demski | 男 | Director | 64 | 21.32万美元 | 未持股 | 2023-05-01 |
| Michael H. Carrel | 男 | Chairman of the Board | 52 | 24.15万美元 | 未持股 | 2023-05-01 |
| Raymond W. Cohen | 男 | Chief Executive Officer, Director | 64 | 532.96万美元 | 74.82 | 2023-05-01 |
| Robert McNamara | 男 | Director | 66 | 23.07万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Karen Noblett | 女 | Chief Medical Officer | 60 | 65.14万美元 | 未持股 | 2023-05-01 |
| Alfred Ford | 男 | Chief Commercial Officer | 53 | 217.34万美元 | 未持股 | 2023-05-01 |
| John Woock | 男 | Executive Vice President, Chief Marketing & Strategy Officer | 40 | 268.38万美元 | 未持股 | 2023-05-01 |
| Dan L. Dearen | 男 | President, Chief Financial Officer | 60 | 181.88万美元 | 未持股 | 2023-05-01 |
| Rinda K. Sama | 男 | Chief Operating Officer | 44 | 268.38万美元 | 22.96 | 2023-05-01 |
| Raymond W. Cohen | 男 | Chief Executive Officer, Director | 64 | 532.96万美元 | 74.82 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Nancy Snyderman
-
Nancy Snyderman自2019年4月起担任董事会成员以及提名和公司治理委员会成员。Snyderman博士自2016年起担任Alkermes plc纳斯达克股票代码:ALKS的董事会独立董事，并担任提名和公司治理委员会成员。Snyderman博士在GE&；8217；S HealthyMagination担任了12年的顾问委员会成员，之前曾担任强生公司公司的企业传播Vice President。Snyderman博士是董事会认证的头颈外科医生，曾在宾夕法尼亚大学（University of Pennsylvania）和加州大学旧金山分校（University of California-San Francisco）有学术约会。她最近担任斯坦福大学全球健康创新中心（Center for Innovation for Global Health）的教授。Snyderman博士是艾美奖医学记者，1987年至2003年在ABC News工作，2004年至2015年在NBC News担任首席医学编辑。她曾广泛发表在同行评审的医学期刊上，并为Good Householding、AARP、Parenting、Health和O Magazine撰写文章。Snyderman博士是女性健康的倡导者和多产的公共演说家，目前任职于Fair Food Network和Wellesley College奥尔布赖特研究所的董事会。Snyderman博士拥有印第安纳大学（Indiana University）的微生物学学士学位和内布拉斯加大学（University of Nebraska）的医学博士学位，并已在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻咽喉头颈外科住院医师。
Nancy Snyderman has served as a member of our compensation committee since December 2020 a member of the Board and a member of our nominating and corporate governance committee since April 2019. Dr. Snyderman has served as an independent director on the board of directors of Alkermes plc NASDAQ: ALKS and as a member of the nominating and corporate governance committee since 2016. Dr. Snyderman was an advisory board member to GE's Healthymagination for twelve years and previously served as a vice president for corporate communications at Johnson & Johnson. Dr. Snyderman is a board-certified head and neck surgeon and has had academic appointments at the University of Pennsylvania and the University of California-San Francisco. She recently served as a professor at the Center for Innovation for Global Health at Stanford University. Dr. Snyderman is an Emmy award winning medical correspondent having worked at ABC News from 1987 to 2003 and later as chief medical editor at NBC News from 2004 to 2015. She has been widely published in peer-reviewed medical journals and has written for Good Housekeeping, AARP, Parenting, Health, and O magazines. Dr. Snyderman is an advocate for women's health and a prolific public speaker and presently serves on the board of directors of Fair Food Network and the Albright Institute at Wellesley College. Dr. Snyderman holds a B.A. in microbiology from Indiana University and an M.D. from the University of Nebraska and has completed residencies in Pediatrics and Otolaryngology Head and Neck Surgery at the University of Pittsburgh. - Nancy Snyderman自2019年4月起担任董事会成员以及提名和公司治理委员会成员。Snyderman博士自2016年起担任Alkermes plc纳斯达克股票代码:ALKS的董事会独立董事，并担任提名和公司治理委员会成员。Snyderman博士在GE&；8217；S HealthyMagination担任了12年的顾问委员会成员，之前曾担任强生公司公司的企业传播Vice President。Snyderman博士是董事会认证的头颈外科医生，曾在宾夕法尼亚大学（University of Pennsylvania）和加州大学旧金山分校（University of California-San Francisco）有学术约会。她最近担任斯坦福大学全球健康创新中心（Center for Innovation for Global Health）的教授。Snyderman博士是艾美奖医学记者，1987年至2003年在ABC News工作，2004年至2015年在NBC News担任首席医学编辑。她曾广泛发表在同行评审的医学期刊上，并为Good Householding、AARP、Parenting、Health和O Magazine撰写文章。Snyderman博士是女性健康的倡导者和多产的公共演说家，目前任职于Fair Food Network和Wellesley College奥尔布赖特研究所的董事会。Snyderman博士拥有印第安纳大学（Indiana University）的微生物学学士学位和内布拉斯加大学（University of Nebraska）的医学博士学位，并已在匹兹堡大学（University of Pittsburgh）完成儿科和耳鼻咽喉头颈外科住院医师。
- Nancy Snyderman has served as a member of our compensation committee since December 2020 a member of the Board and a member of our nominating and corporate governance committee since April 2019. Dr. Snyderman has served as an independent director on the board of directors of Alkermes plc NASDAQ: ALKS and as a member of the nominating and corporate governance committee since 2016. Dr. Snyderman was an advisory board member to GE's Healthymagination for twelve years and previously served as a vice president for corporate communications at Johnson & Johnson. Dr. Snyderman is a board-certified head and neck surgeon and has had academic appointments at the University of Pennsylvania and the University of California-San Francisco. She recently served as a professor at the Center for Innovation for Global Health at Stanford University. Dr. Snyderman is an Emmy award winning medical correspondent having worked at ABC News from 1987 to 2003 and later as chief medical editor at NBC News from 2004 to 2015. She has been widely published in peer-reviewed medical journals and has written for Good Housekeeping, AARP, Parenting, Health, and O magazines. Dr. Snyderman is an advocate for women's health and a prolific public speaker and presently serves on the board of directors of Fair Food Network and the Albright Institute at Wellesley College. Dr. Snyderman holds a B.A. in microbiology from Indiana University and an M.D. from the University of Nebraska and has completed residencies in Pediatrics and Otolaryngology Head and Neck Surgery at the University of Pittsburgh.
- Esteban López
-
Esteban L ó pez，自2021年7月起担任董事会成员。自2021年1月以来，他一直担任家庭护理服务上市提供商Addus HomeCare Corporation（NASDAQ：ADUS）的董事会成员，并且是Hopscotch Health的创始人兼首席执行官，该公司是一家专注于儿童紧急护理需求的临床实践机构。2020年9月至2023年3月，他在Google Cloud担任美洲医疗保健和生命科学市场负责人，负责战略和解决方案开发的跨国执行。2013年3月至2019年12月，他曾在Health Care Service Corporation（HCSC）担任多个执行职务，最近担任临床战略和创新首席医疗官。HCSC是美国第四大健康保险公司，L ó pez博士获得了加州大学圣克鲁斯分校的生物学学士学位、密歇根州立大学人类医学学院的医学博士学位和得克萨斯大学达拉斯分校的工商管理硕士学位。L ó pez博士获得了内科和儿科的双板认证，并继续在Hopscotch Health的空闲时间行医。由于L ó pez博士在医疗保健行业拥有广泛的知识和经验，因此他有资格担任Axonics, Inc.董事会成员。
Esteban López,has served as a member of the Board since July 2021. Since January 2021 he has served on the Board of Directors of Addus HomeCare Corporation (NASDAQ: ADUS), a publicly traded provider of home care services, and is the founder and CEO of Hopscotch Health, a clinical practice focused on children's urgent care needs. From September 2020 to March 2023, he served as the Americas Healthcare and Life sciences Market Lead at Google Cloud with multinational executive responsibility for strategy and solutions development. From March 2013 to December 2019, he worked at Health Care Service Corporation (HCSC) in several executive roles most recently as Chief Medical Officer for Clinical Strategy and Innovation. HCSC is the fourth largest health insurer in the U.S. Dr. López received a B.A. in biology from the University of California, Santa Cruz, his M.D. from Michigan State University College of Human Medicine, and his M.B.A. from the University of Texas at Dallas. Dr. López is dual Board Certified in both Internal Medicine and Pediatrics and continues to practice medicine in his free time at Hopscotch Health. - Esteban L ó pez，自2021年7月起担任董事会成员。自2021年1月以来，他一直担任家庭护理服务上市提供商Addus HomeCare Corporation（NASDAQ：ADUS）的董事会成员，并且是Hopscotch Health的创始人兼首席执行官，该公司是一家专注于儿童紧急护理需求的临床实践机构。2020年9月至2023年3月，他在Google Cloud担任美洲医疗保健和生命科学市场负责人，负责战略和解决方案开发的跨国执行。2013年3月至2019年12月，他曾在Health Care Service Corporation（HCSC）担任多个执行职务，最近担任临床战略和创新首席医疗官。HCSC是美国第四大健康保险公司，L ó pez博士获得了加州大学圣克鲁斯分校的生物学学士学位、密歇根州立大学人类医学学院的医学博士学位和得克萨斯大学达拉斯分校的工商管理硕士学位。L ó pez博士获得了内科和儿科的双板认证，并继续在Hopscotch Health的空闲时间行医。由于L ó pez博士在医疗保健行业拥有广泛的知识和经验，因此他有资格担任Axonics, Inc.董事会成员。
- Esteban López,has served as a member of the Board since July 2021. Since January 2021 he has served on the Board of Directors of Addus HomeCare Corporation (NASDAQ: ADUS), a publicly traded provider of home care services, and is the founder and CEO of Hopscotch Health, a clinical practice focused on children's urgent care needs. From September 2020 to March 2023, he served as the Americas Healthcare and Life sciences Market Lead at Google Cloud with multinational executive responsibility for strategy and solutions development. From March 2013 to December 2019, he worked at Health Care Service Corporation (HCSC) in several executive roles most recently as Chief Medical Officer for Clinical Strategy and Innovation. HCSC is the fourth largest health insurer in the U.S. Dr. López received a B.A. in biology from the University of California, Santa Cruz, his M.D. from Michigan State University College of Human Medicine, and his M.B.A. from the University of Texas at Dallas. Dr. López is dual Board Certified in both Internal Medicine and Pediatrics and continues to practice medicine in his free time at Hopscotch Health.
- Jane E. Kiernan
-
Jane E. Kiernan，她一直担任Salter Labs的首席执行官（2010年以来）。从2007年到2010年，她曾担任Baxter Healthcare Corporation（上市公司Baxter International公司的首席运营子公司）的勃脉力总经理。从2003年到2007年3月，她曾担任Baxter Nutrition（Baxter Healthcare Corporation的一个部门，肠外营养产品的供应商）的总经理。从2001年到2003年，她曾担任Specialty Therapies公司（Baxter Healthcare Corporation的其它部门）的总经理。从2000年到2001年，她曾担任Baxter Healthcare Corporation的战略副总裁。从1995年到2000年，她曾担任Allegiance Healthcare Corporation（医疗产品和服务的供应商）的负责财务、分销和服务的副总裁。
Jane E. Kiernan has served as Chair of our compensation committee since December 2020 and a member of the Board, a member of our audit committee, and a member of our compensation committee since April 2019. Ms. Kiernan has over 30 years of executive and management leadership in health care with both public and private companies. Ms. Kiernan is a co-founder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, health care corporations and philanthropic health care foundation partners. From 2010 to 2017 Ms. Kiernan served as the Chief Executive Officer of Salter Labs, a manufacturer of specialty medical devices. From 2006 to 2011 Ms. Kiernan served on the board of directors and as Chair of the audit committee of American Medical Systems Holdings Inc. prior to it being acquired by Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., a subsidiary of Endo International plc. From 2001 to 2010 Ms. Kiernan held executive and general management positions with Baxter Healthcare Corporation. Prior to 2001 she held corporate and line management roles in finance, strategy, marketing, and operations with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Ms. Kiernan serves on the board of directors of Ryan Banks Academy, an urban boarding school in Chicago, and has served as committee Chair and on the board of directors of the American Red Cross of Greater Chicago. In addition, she is a past president of the Healthcare Businesswomen's Association, Chicago Chapter. Ms. Kiernan holds a B.S. in business from Southern Methodist University. - Jane E. Kiernan，她一直担任Salter Labs的首席执行官（2010年以来）。从2007年到2010年，她曾担任Baxter Healthcare Corporation（上市公司Baxter International公司的首席运营子公司）的勃脉力总经理。从2003年到2007年3月，她曾担任Baxter Nutrition（Baxter Healthcare Corporation的一个部门，肠外营养产品的供应商）的总经理。从2001年到2003年，她曾担任Specialty Therapies公司（Baxter Healthcare Corporation的其它部门）的总经理。从2000年到2001年，她曾担任Baxter Healthcare Corporation的战略副总裁。从1995年到2000年，她曾担任Allegiance Healthcare Corporation（医疗产品和服务的供应商）的负责财务、分销和服务的副总裁。
- Jane E. Kiernan has served as Chair of our compensation committee since December 2020 and a member of the Board, a member of our audit committee, and a member of our compensation committee since April 2019. Ms. Kiernan has over 30 years of executive and management leadership in health care with both public and private companies. Ms. Kiernan is a co-founder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, health care corporations and philanthropic health care foundation partners. From 2010 to 2017 Ms. Kiernan served as the Chief Executive Officer of Salter Labs, a manufacturer of specialty medical devices. From 2006 to 2011 Ms. Kiernan served on the board of directors and as Chair of the audit committee of American Medical Systems Holdings Inc. prior to it being acquired by Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., a subsidiary of Endo International plc. From 2001 to 2010 Ms. Kiernan held executive and general management positions with Baxter Healthcare Corporation. Prior to 2001 she held corporate and line management roles in finance, strategy, marketing, and operations with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Ms. Kiernan serves on the board of directors of Ryan Banks Academy, an urban boarding school in Chicago, and has served as committee Chair and on the board of directors of the American Red Cross of Greater Chicago. In addition, she is a past president of the Healthcare Businesswomen's Association, Chicago Chapter. Ms. Kiernan holds a B.S. in business from Southern Methodist University.
- David M. Demski
-
David M. Demski，自2008年8月起，他担任Globus Medical, Inc.的总裁和首席运营官；自公司于2003年成立，他担任Globus Medical的董事；他是Globus Medical提名和公司治理委员会的成员；自2003年至2008年7月，他担任Globus Medical的首席财务官。在2003年加入Globus之前，他创立了 Cornerstone Capital LBO Fund，这是一个时装融资收买咨询公司。他的经验还包括：自2000年至2001年，担任 Gilo Ventures（一个位于硅谷的风险资本基金公司）的副总裁；以及自1994年至2000年，担任 Rendall and Associates（一个专注于电信业的咨询公司）的首席运营官。上个世纪80年代末，在公司的增长期间，他还管理Domino的披萨在地区和国际的配送。之前，他是Peat, Marwick, Mitchell & Company的审计监督员。他取得了 the University of Michigan的工商管理学学士学位，以及the Stanford Graduate 商学院的工商管理学硕士学位。
David M. Demski has served a member of the Board and a member of Globus Medical, Inc. audit committee since January 2021. Since August 2019 he has served as President, Chief Executive Officer and director of Globus Medical NASDAQ: GLBS. Between August 2017 and August 2019 he served as Chief Executive Officer of Globus Medical. He has served as a director since Globus Medical's inception in 2003 and is a member of the Nominating and Corporate Governance Committee. Between September 2015 and August 2017 Mr. Demski served as President, Emerging Technologies. He served as President and Chief Operating Officer from August 2008 until September 2015 and as Chief Financial Officer from 2003 until August 2008. Prior to joining Globus in 2003 Mr. Demski founded Cornerstone Capital LBO Fund, a boutique leveraged-buyout consultancy. Mr. Demski's experience also includes serving as Vice President for Gilo Ventures, a Silicon Valley-based venture capital fund, from 2000 to 2001 and serving as Chief Operating Officer of Rendall and Associates, a telecommunications-focused consulting firm, from 1994 to 2000. He also managed regional and international distribution for Domino's Pizza during the company's growth in the late 1980s. Previously, he was an audit supervisor for Peat, Marwick, Mitchell & Company. Mr. Demski received a B.S. in Business Administration from the University of Michigan and an M.B.A. from the Stanford Graduate School of Business. - David M. Demski，自2008年8月起，他担任Globus Medical, Inc.的总裁和首席运营官；自公司于2003年成立，他担任Globus Medical的董事；他是Globus Medical提名和公司治理委员会的成员；自2003年至2008年7月，他担任Globus Medical的首席财务官。在2003年加入Globus之前，他创立了 Cornerstone Capital LBO Fund，这是一个时装融资收买咨询公司。他的经验还包括：自2000年至2001年，担任 Gilo Ventures（一个位于硅谷的风险资本基金公司）的副总裁；以及自1994年至2000年，担任 Rendall and Associates（一个专注于电信业的咨询公司）的首席运营官。上个世纪80年代末，在公司的增长期间，他还管理Domino的披萨在地区和国际的配送。之前，他是Peat, Marwick, Mitchell & Company的审计监督员。他取得了 the University of Michigan的工商管理学学士学位，以及the Stanford Graduate 商学院的工商管理学硕士学位。
- David M. Demski has served a member of the Board and a member of Globus Medical, Inc. audit committee since January 2021. Since August 2019 he has served as President, Chief Executive Officer and director of Globus Medical NASDAQ: GLBS. Between August 2017 and August 2019 he served as Chief Executive Officer of Globus Medical. He has served as a director since Globus Medical's inception in 2003 and is a member of the Nominating and Corporate Governance Committee. Between September 2015 and August 2017 Mr. Demski served as President, Emerging Technologies. He served as President and Chief Operating Officer from August 2008 until September 2015 and as Chief Financial Officer from 2003 until August 2008. Prior to joining Globus in 2003 Mr. Demski founded Cornerstone Capital LBO Fund, a boutique leveraged-buyout consultancy. Mr. Demski's experience also includes serving as Vice President for Gilo Ventures, a Silicon Valley-based venture capital fund, from 2000 to 2001 and serving as Chief Operating Officer of Rendall and Associates, a telecommunications-focused consulting firm, from 1994 to 2000. He also managed regional and international distribution for Domino's Pizza during the company's growth in the late 1980s. Previously, he was an audit supervisor for Peat, Marwick, Mitchell & Company. Mr. Demski received a B.S. in Business Administration from the University of Michigan and an M.B.A. from the Stanford Graduate School of Business.
- Michael H. Carrel
-
Michael H. Carrel，他担任主席，首席执行官和董事（2012年11月以来）。他担任Vital Images（上市医疗成像软件公司）的总裁兼首席执行官（从2008年到2012年）。他最初于2005年1月加入Vital Images，担任首席运营官和首席财务官。在Vital Images 任职期间，他领导公司成为保健和医疗软件行业的领导者。在他的领导下，公司的收入和利润增长，全球市场份额增加，遍布90多个国家，并股权融资筹集了1亿美元。此前，他担任Zamba集团（上市科技公司）的总裁兼首席执行官，以及NextNet Wireless（即插即用宽带无线接入系统的私人供应商，现在属于摩托罗拉公司）的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
Michael H. Carrel has served as a member of our nominating and corporate governance committee since December 2020 a member of the Board and a member of our compensation committee since February 2019 and was named Chairman of the Board on April 28 2020. Since November 2012 Mr. Carrel has served as President, Chief Executive Officer and director of AtriCure, Inc. NASDAQ: ATRC, a medical device company that provides solutions for the treatment of atrial fibrillation and related conditions. Prior, Mr. Carrel served as President and Chief Executive Officer of Vital Images, Inc., a publicly traded medical imaging software company. Prior to Vital Images, Inc., Mr. Carrel was President and CEO of Zamba Corporation, a publicly traded technology company, and Chief Financial Officer of NextNet Wireless, a privately held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel is a member of the board of directors of Lombard Medical, Inc., a manufacturer and marketer of abdominal aortic aneurysm stent graphs, the Medical Device Manufacturers Association and the American Heart Association Chapter in Minneapolis. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania. - Michael H. Carrel，他担任主席，首席执行官和董事（2012年11月以来）。他担任Vital Images（上市医疗成像软件公司）的总裁兼首席执行官（从2008年到2012年）。他最初于2005年1月加入Vital Images，担任首席运营官和首席财务官。在Vital Images 任职期间，他领导公司成为保健和医疗软件行业的领导者。在他的领导下，公司的收入和利润增长，全球市场份额增加，遍布90多个国家，并股权融资筹集了1亿美元。此前，他担任Zamba集团（上市科技公司）的总裁兼首席执行官，以及NextNet Wireless（即插即用宽带无线接入系统的私人供应商，现在属于摩托罗拉公司）的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
- Michael H. Carrel has served as a member of our nominating and corporate governance committee since December 2020 a member of the Board and a member of our compensation committee since February 2019 and was named Chairman of the Board on April 28 2020. Since November 2012 Mr. Carrel has served as President, Chief Executive Officer and director of AtriCure, Inc. NASDAQ: ATRC, a medical device company that provides solutions for the treatment of atrial fibrillation and related conditions. Prior, Mr. Carrel served as President and Chief Executive Officer of Vital Images, Inc., a publicly traded medical imaging software company. Prior to Vital Images, Inc., Mr. Carrel was President and CEO of Zamba Corporation, a publicly traded technology company, and Chief Financial Officer of NextNet Wireless, a privately held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel is a member of the board of directors of Lombard Medical, Inc., a manufacturer and marketer of abdominal aortic aneurysm stent graphs, the Medical Device Manufacturers Association and the American Heart Association Chapter in Minneapolis. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
- Raymond W. Cohen
-
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University. - Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.
- Robert McNamara
-
Robert McNamara，自2018年2月起担任董事会成员。他在医疗器械行业拥有超过25年的经验。他还担任AVITA Medical， Inc. （RCEL）的董事会成员、审计委员会主席、薪酬委员会成员和提名和治理委员会成员。从2013年1月到2016年7月，他担任LDR Holding Corporation（一家上市的医疗设备（脊柱植入物）公司）的执行副总裁，并从2012年4月到2016年7月担任首席财务官，该公司被Zimmer Biomet Holdings， Inc.收购。此外，McNamara先生曾担任公开上市的医疗设备公司的高级副总裁兼首席财务官，包括Accuray Inc.（一家立体定向辐射公司，专注于治疗癌症）、Xtant medical Holdings, Inc.（人工智能机器人）、Somnus medical Technologies Inc.（一家射频能源公司，专注于治疗上呼吸道呼吸障碍）和Target Therapeutics， Inc.。一家治疗脑部血管疾病的微创导管和设备公司。McNamara先生此前曾担任Axonics， Inc., Alpha Teknova, Inc.和Northstar Neurosciences Inc.的董事会成员，也是加州门洛帕克的前市长。McNamara先生的职业生涯始于公共会计，是一名注册会计师（目前不活跃）。他持有San Francisco大学的会计学士学位和the Wharton School的工商管理硕士学位。
Robert McNamara,has served as a member of Board since February 2018. He has over 25 years of experience in the medical device industry.He also serves on the board of directors and as Audit Committee Chair, member of the Compensation Committee and a member of the Nominating and Governance Committee of AVITA Medical, Inc. (RCEL). From January 2013 to July 2016, Mr. McNamara served as Executive Vice President and from April 2012 to July 2016 as the Chief Financial Officer for LDR Holding Corporation, a publicly held medical device (spinal implants) company acquired by Zimmer Biomet Holdings, Inc. In addition, Mr. McNamara has previously served as the Senior Vice President and Chief Financial Officer for publicly traded medical device companies including Accuray Inc., a stereotactic radiation company focused on treating cancer Xtant Medical Holdings, Inc. ing AI robotics, Somnus Medical Technologies Inc., a RF energy company focused on treating upper airway breathing disorders, and Target Therapeutics, Inc., a minimally invasive catheter and device company treating vascular diseases of the brain. Mr. McNamara previously served as a member of the board of directors of Axonics, Inc., Alpha Teknova, Inc. and Northstar Neurosciences Inc. and is the former Mayor of Menlo Park, California. Mr. McNamara began his career in public accounting and is a certified public accountant (current status inactive). Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and a Master of Business Administration in Finance from The Wharton School at the University of Pennsylvania. - Robert McNamara，自2018年2月起担任董事会成员。他在医疗器械行业拥有超过25年的经验。他还担任AVITA Medical， Inc. （RCEL）的董事会成员、审计委员会主席、薪酬委员会成员和提名和治理委员会成员。从2013年1月到2016年7月，他担任LDR Holding Corporation（一家上市的医疗设备（脊柱植入物）公司）的执行副总裁，并从2012年4月到2016年7月担任首席财务官，该公司被Zimmer Biomet Holdings， Inc.收购。此外，McNamara先生曾担任公开上市的医疗设备公司的高级副总裁兼首席财务官，包括Accuray Inc.（一家立体定向辐射公司，专注于治疗癌症）、Xtant medical Holdings, Inc.（人工智能机器人）、Somnus medical Technologies Inc.（一家射频能源公司，专注于治疗上呼吸道呼吸障碍）和Target Therapeutics， Inc.。一家治疗脑部血管疾病的微创导管和设备公司。McNamara先生此前曾担任Axonics， Inc., Alpha Teknova, Inc.和Northstar Neurosciences Inc.的董事会成员，也是加州门洛帕克的前市长。McNamara先生的职业生涯始于公共会计，是一名注册会计师（目前不活跃）。他持有San Francisco大学的会计学士学位和the Wharton School的工商管理硕士学位。
- Robert McNamara,has served as a member of Board since February 2018. He has over 25 years of experience in the medical device industry.He also serves on the board of directors and as Audit Committee Chair, member of the Compensation Committee and a member of the Nominating and Governance Committee of AVITA Medical, Inc. (RCEL). From January 2013 to July 2016, Mr. McNamara served as Executive Vice President and from April 2012 to July 2016 as the Chief Financial Officer for LDR Holding Corporation, a publicly held medical device (spinal implants) company acquired by Zimmer Biomet Holdings, Inc. In addition, Mr. McNamara has previously served as the Senior Vice President and Chief Financial Officer for publicly traded medical device companies including Accuray Inc., a stereotactic radiation company focused on treating cancer Xtant Medical Holdings, Inc. ing AI robotics, Somnus Medical Technologies Inc., a RF energy company focused on treating upper airway breathing disorders, and Target Therapeutics, Inc., a minimally invasive catheter and device company treating vascular diseases of the brain. Mr. McNamara previously served as a member of the board of directors of Axonics, Inc., Alpha Teknova, Inc. and Northstar Neurosciences Inc. and is the former Mayor of Menlo Park, California. Mr. McNamara began his career in public accounting and is a certified public accountant (current status inactive). Mr. McNamara holds a Bachelor of Science in Accounting from the University of San Francisco and a Master of Business Administration in Finance from The Wharton School at the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Karen Noblett
Karen Noblett自2017年10月起担任首席医疗官。2014年1月至2017年9月，Noblett博士担任我们的医师顾问。2014年8月至2017年9月，Noblett博士担任加州大学河滨分校妇产科教授兼系主任。从1999年1月到2014年7月，Noblett博士担任加州大学欧文分校（University of California，Irvine）的教授兼部门总监。Noblett博士拥有加州州立大学弗雷斯诺分校（California State University，Fresno）的生物学学士学位，加州大学欧文分校（University of California，Irvine）的医学博士学位，加州大学圣地亚哥分校（University of California，San Diego）的研究硕士学位和加州大学欧文分校（University of California，Irvine）的工商管理硕士学位。
Karen Noblett has served as our Chief Medical Officer since October 2017 and as a physician advisor to Axonics from January 2014 until joining us as an employee. From August 2014 to September 2017 Dr. Noblett served as Professor and Department Chair, OB/GYN, at the University of California, Riverside. From October 1998 to July 2014 Dr. Noblett served as Professor and Division Director at the University of California, Irvine. From July 1995 to June 1998 Dr. Noblett completed her fellowship in Female Pelvic Medicine and Reconstructive Surgery and from July 1991 to June 1995 she completed her residency in Obstetrics and Gynecology at the University of California, Irvine. Dr. Noblett holds a B.A. in Biology from California State University, Fresno, an M.D. from the University of California, Irvine, and an M.S. in Research from the University of California, San Diego.- Karen Noblett自2017年10月起担任首席医疗官。2014年1月至2017年9月，Noblett博士担任我们的医师顾问。2014年8月至2017年9月，Noblett博士担任加州大学河滨分校妇产科教授兼系主任。从1999年1月到2014年7月，Noblett博士担任加州大学欧文分校（University of California，Irvine）的教授兼部门总监。Noblett博士拥有加州州立大学弗雷斯诺分校（California State University，Fresno）的生物学学士学位，加州大学欧文分校（University of California，Irvine）的医学博士学位，加州大学圣地亚哥分校（University of California，San Diego）的研究硕士学位和加州大学欧文分校（University of California，Irvine）的工商管理硕士学位。
- Karen Noblett has served as our Chief Medical Officer since October 2017 and as a physician advisor to Axonics from January 2014 until joining us as an employee. From August 2014 to September 2017 Dr. Noblett served as Professor and Department Chair, OB/GYN, at the University of California, Riverside. From October 1998 to July 2014 Dr. Noblett served as Professor and Division Director at the University of California, Irvine. From July 1995 to June 1998 Dr. Noblett completed her fellowship in Female Pelvic Medicine and Reconstructive Surgery and from July 1991 to June 1995 she completed her residency in Obstetrics and Gynecology at the University of California, Irvine. Dr. Noblett holds a B.A. in Biology from California State University, Fresno, an M.D. from the University of California, Irvine, and an M.S. in Research from the University of California, San Diego.
- Alfred Ford
Alfred Ford自2017年11月起担任我们的首席商务官。从1997年1月至2017年6月，福特先生担任外部自动除颤器制造商Cardiac Science，Inc.的总裁兼首席商务官，Vice President，全球销售与营销，Vice President，销售，分销总监，区域销售经理和地区经理。Ford先生在圣约瑟夫大学（Saint Joseph&8217；s University）获得营销学学士学位和国际营销学硕士学位。
Alfred Ford, Jr. has served as our Chief Commercial Officer since November 2017. From January 1997 to June 2017 Mr. Ford served as President and Chief Commercial Officer, General Manager, Vice President, Global Sales & Marketing, Vice President, Sales, Distribution Director, Regional Sales Manager and Territory Manager of Cardiac Science, Inc., a manufacturer of external automatic defibrillators. Mr. Ford holds a B.S. in Marketing and an M.S. in International Marketing from Saint Joseph's University.- Alfred Ford自2017年11月起担任我们的首席商务官。从1997年1月至2017年6月，福特先生担任外部自动除颤器制造商Cardiac Science，Inc.的总裁兼首席商务官，Vice President，全球销售与营销，Vice President，销售，分销总监，区域销售经理和地区经理。Ford先生在圣约瑟夫大学（Saint Joseph&8217；s University）获得营销学学士学位和国际营销学硕士学位。
- Alfred Ford, Jr. has served as our Chief Commercial Officer since November 2017. From January 1997 to June 2017 Mr. Ford served as President and Chief Commercial Officer, General Manager, Vice President, Global Sales & Marketing, Vice President, Sales, Distribution Director, Regional Sales Manager and Territory Manager of Cardiac Science, Inc., a manufacturer of external automatic defibrillators. Mr. Ford holds a B.S. in Marketing and an M.S. in International Marketing from Saint Joseph's University.
- John Woock
John Woock自2018年6月起担任我们的首席营销官。在此之前，Woock先生于2017年1月至2018年5月担任我们的全球营销和临床运营副总裁，并于2014年6月至2016年12月担任我们的产品营销副总裁。任职我们公司之前，他曾担任Stanford University的斯坦福生物设计项目的博士后（2013年8月至2014年6月）。Woock先生拥有圣路易斯华盛顿大学（Washington University）生物医学工程学士学位和杜克大学（Duke University）生物医学工程博士学位。
John Woock has served as our Chief Marketing Officer since June 2018. Prior to that time, Mr. Woock served as our VP, Global Marketing and Clinical Operations from January 2017 to May 2018 and our VP, Product Marketing from June 2014 to December 2016. Before working with our company, he was a postdoctoral fellow at the Stanford Biodesign Program at Stanford University from August 2013 to June 2014. Mr. Woock holds a B.S. in Biomedical Engineering from Washington University in St. Louis and a Ph.D. in biomedical engineering from Duke University.- John Woock自2018年6月起担任我们的首席营销官。在此之前，Woock先生于2017年1月至2018年5月担任我们的全球营销和临床运营副总裁，并于2014年6月至2016年12月担任我们的产品营销副总裁。任职我们公司之前，他曾担任Stanford University的斯坦福生物设计项目的博士后（2013年8月至2014年6月）。Woock先生拥有圣路易斯华盛顿大学（Washington University）生物医学工程学士学位和杜克大学（Duke University）生物医学工程博士学位。
- John Woock has served as our Chief Marketing Officer since June 2018. Prior to that time, Mr. Woock served as our VP, Global Marketing and Clinical Operations from January 2017 to May 2018 and our VP, Product Marketing from June 2014 to December 2016. Before working with our company, he was a postdoctoral fellow at the Stanford Biodesign Program at Stanford University from August 2013 to June 2014. Mr. Woock holds a B.S. in Biomedical Engineering from Washington University in St. Louis and a Ph.D. in biomedical engineering from Duke University.
- Dan L. Dearen
DanL.Dearen自2018年8月起担任我们的总裁，自2013年10月起担任我们的首席财务官。2013年10月至2018年8月，Dearen先生担任我们的首席运营官。2009年7月至2013年10月，Dearen先生担任Vessix Vascular，Inc.的首席运营官和首席财务官，该公司是一家用于治疗无法控制的高血压的新型肾去神经系统的开发商，该公司被波士顿科学国际有限公司收购。Dearen先生拥有南卫理公会大学（Southern Methodist University）的工商管理学士学位和波士顿学院（Boston College）的工商管理硕士学位。
Dan L. Dearen has served as our President since August 2018 and our Chief Financial Officer since October 2013. From October 2013 to August 2018 Mr. Dearen served as our Chief Operating Officer. From July 2009 to October 2013 Mr. Dearen served as Chief Operating Officer and Chief Financial Officer of Vessix Vascular, Inc., a developer of a novel renal denervation system used to treat uncontrolled hypertension, which was acquired by Boston Scientific Corporation. Previously, he served as Chief Financial Officer of Miraval Holding, Q3DM, Medication Delivery Devices and was a Principal at Ventana Growth Funds, an international venture capital firm investing in medical devices, life sciences and healthcare companies. Mr. Dearen started his career as a CPA inactive in the healthcare group at Ernst & Young in Dallas, Texas. He holds a B.B.A. in Accounting & Business from Southern Methodist University and an M.B.A. from Boston College and completed the Accredited Public Company Director Certification program at the University of California Los Angeles. In March of 2021 Mr. Dearen joined the Board of Directors of Endotronix, Inc., a digital health and medical technology company, as an Independent Director and Chair of the Audit Committee.- DanL.Dearen自2018年8月起担任我们的总裁，自2013年10月起担任我们的首席财务官。2013年10月至2018年8月，Dearen先生担任我们的首席运营官。2009年7月至2013年10月，Dearen先生担任Vessix Vascular，Inc.的首席运营官和首席财务官，该公司是一家用于治疗无法控制的高血压的新型肾去神经系统的开发商，该公司被波士顿科学国际有限公司收购。Dearen先生拥有南卫理公会大学（Southern Methodist University）的工商管理学士学位和波士顿学院（Boston College）的工商管理硕士学位。
- Dan L. Dearen has served as our President since August 2018 and our Chief Financial Officer since October 2013. From October 2013 to August 2018 Mr. Dearen served as our Chief Operating Officer. From July 2009 to October 2013 Mr. Dearen served as Chief Operating Officer and Chief Financial Officer of Vessix Vascular, Inc., a developer of a novel renal denervation system used to treat uncontrolled hypertension, which was acquired by Boston Scientific Corporation. Previously, he served as Chief Financial Officer of Miraval Holding, Q3DM, Medication Delivery Devices and was a Principal at Ventana Growth Funds, an international venture capital firm investing in medical devices, life sciences and healthcare companies. Mr. Dearen started his career as a CPA inactive in the healthcare group at Ernst & Young in Dallas, Texas. He holds a B.B.A. in Accounting & Business from Southern Methodist University and an M.B.A. from Boston College and completed the Accredited Public Company Director Certification program at the University of California Los Angeles. In March of 2021 Mr. Dearen joined the Board of Directors of Endotronix, Inc., a digital health and medical technology company, as an Independent Director and Chair of the Audit Committee.
- Rinda K. Sama
RindaK.Sama自2018年8月起担任我们的首席运营官。2014年5月至2018年8月，Sama先生担任我们的Vice President，运营和质量。Sama从2011年6月到2014年5月担任Vessix Vascular，Inc.运营和质量主管。Sama先生拥有卡纳塔克大学达尔瓦德分校（Karnatak University Dharwad）生物医学工程学士学位，南加州大学（University of Southern California）生物医学工程硕士学位和加州大学欧文分校（University of California，Irvine）工商管理硕士学位。
Rinda K. Sama has served as our Chief Operating Officer since August 2018. From May 2014 to August 2018 Mr. Sama served as our Vice President, Operations and Quality. From June 2011 to May 2014 Mr. Sama served as Director, Operations and Quality of Vessix Vascular, Inc. Mr. Sama holds a B.S. in Biomedical Engineering from Karnatak University Dharwad, a M.S. in Biomedical Engineering from the University of Southern California and an M.B.A from the University of California, Irvine.- RindaK.Sama自2018年8月起担任我们的首席运营官。2014年5月至2018年8月，Sama先生担任我们的Vice President，运营和质量。Sama从2011年6月到2014年5月担任Vessix Vascular，Inc.运营和质量主管。Sama先生拥有卡纳塔克大学达尔瓦德分校（Karnatak University Dharwad）生物医学工程学士学位，南加州大学（University of Southern California）生物医学工程硕士学位和加州大学欧文分校（University of California，Irvine）工商管理硕士学位。
- Rinda K. Sama has served as our Chief Operating Officer since August 2018. From May 2014 to August 2018 Mr. Sama served as our Vice President, Operations and Quality. From June 2011 to May 2014 Mr. Sama served as Director, Operations and Quality of Vessix Vascular, Inc. Mr. Sama holds a B.S. in Biomedical Engineering from Karnatak University Dharwad, a M.S. in Biomedical Engineering from the University of Southern California and an M.B.A from the University of California, Irvine.
- Raymond W. Cohen
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.- Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.